Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1346 New Diagnostic and Therapeutic Approaches in Adrenocortical Cancer

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

[1]  M. Fassnacht,et al.  Management of adrenocortical carcinoma , 2004, Clinical endocrinology.

[2]  H. Engler,et al.  Pheochromocytomas: detection with 11C hydroxyephedrine PET. , 2004, Radiology.

[3]  A. D. Van den Abbeele,et al.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  R. Gilbert,et al.  STI-571 inhibits in vitro angiogenesis. , 2003, Biochemical and biophysical research communications.

[5]  H. Friess,et al.  Effects of STI571 (gleevec) on pancreatic cancer cell growth , 2003, Molecular Cancer.

[6]  C. Gicquel,et al.  Clinical and molecular aspects of adrenocortical tumourigenesis , 2003, ANZ journal of surgery.

[7]  R. Voutilainen,et al.  Expression of activin/inhibin signaling components in the human adrenal gland and the effects of activins and inhibins on adrenocortical steroidogenesis and apoptosis. , 2003, The Journal of endocrinology.

[8]  D. Bodurka,et al.  Expression of c‐ABL, c‐KIT, and platelet‐derived growth factor receptor‐β in ovarian serous carcinoma and normal ovarian surface epithelium , 2003, Cancer.

[9]  W. Wadsak,et al.  Comparison of three different purification methods for the routine preparation of [11C] Metomidate. , 2003, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[10]  V. Livolsi,et al.  The Role of Calretinin, Inhibin, Melan-A, BCL-2, and C-kit in Differentiating Adrenal Cortical and Medullary Tumors: An Immunohistochemical Study , 2003, Modern Pathology.

[11]  Y. Matsuzawa,et al.  Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors , 2003, International journal of cancer.

[12]  M. Fjällskog,et al.  Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  Rocco Piazza,et al.  Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. , 2003, The Lancet. Oncology.

[14]  S. Turner,et al.  Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro , 2003, Molecular Cancer.

[15]  A. Bolzán,et al.  Genotoxicity of streptozotocin. , 2002, Mutation research.

[16]  G. Chrousos,et al.  The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. , 2002, The Journal of clinical endocrinology and metabolism.

[17]  G. Demetri,et al.  Management of malignant gastrointestinal stromal tumours. , 2002, The Lancet. Oncology.

[18]  P. Miccoli,et al.  Angiogenesis in human normal and pathologic adrenal cortex. , 2002, The Journal of clinical endocrinology and metabolism.

[19]  A. Baccarelli,et al.  Long-term follow-up study of patients with adrenal incidentalomas. , 2002, European journal of endocrinology.

[20]  L. Ashman,et al.  Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. , 2002, Molecular cancer therapeutics.

[21]  D. Rubello,et al.  Clinical role of positron emission tomography (PET) in endocrine tumours. , 2002, Panminerva medica.

[22]  J. Wood,et al.  Pharmacology of imatinib (STI571). , 2002, European journal of cancer.

[23]  Markku Miettinen,et al.  Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. , 2002, European journal of cancer.

[24]  D. Fabbro,et al.  Imatinib: a selective tyrosine kinase inhibitor. , 2002, European journal of cancer.

[25]  M. Bergström,et al.  The Role of PET in Localization of Neuroendocrine and Adrenocortical Tumors , 2002, Annals of the New York Academy of Sciences.

[26]  B. Ahrén,et al.  Adrenal incidentaloma – experience of a standardized diagnostic programme in the Swedish prospective study , 2002, Journal of internal medicine.

[27]  R. Schwartz.  A molecular star in the wars against cancer. , 2002, The New England journal of medicine.

[28]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[29]  B. Bain,et al.  Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. , 2002, The New England journal of medicine.

[30]  M. K. Magnússon,et al.  Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. , 2002, Blood.

[31]  J. Griffin,et al.  Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease , 2002, Oncogene.

[32]  S. Steinberg,et al.  A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma , 2002, Cancer.

[33]  B. Druker,et al.  Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Reilly.  Class III receptor tyrosine kinases: role in leukaemogenesis , 2002, British journal of haematology.

[35]  C. Cordon-Cardo,et al.  Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  B. Shapiro,et al.  Scintigraphic imaging of the adrenal glands. , 2002, European journal of radiology.

[37]  C. Sawyers.  Rational therapeutic intervention in cancer: kinases as drug targets. , 2002, Current opinion in genetics & development.

[38]  C. J. Chen,et al.  KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. , 2001, Cancer research.

[39]  Sigrid Stroobants,et al.  Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study , 2001, The Lancet.

[40]  E. Baudin,et al.  Impact of monitoring plasma 1,1‐dichlorodiphenildichloroethane (o,p′DDD) levels on the treatment of patients with adrenocortical carcinoma , 2001, Cancer.

[41]  E. Baudin,et al.  Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. , 2001, Cancer research.

[42]  F. Beuschlein,et al.  Discerning malignancy in adrenocortical tumors: are molecular markers useful? , 2001, European journal of endocrinology.

[43]  T. Jacks,et al.  STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications , 2001, Oncogene.

[44]  G. Palù,et al.  Molecular analysis of CDKN1C and TP53 in sporadic adrenal tumors. , 2001, European journal of endocrinology.

[45]  G. Karanikas,et al.  FDG-PET in adrenocortical carcinoma. , 2001, Cancer biotherapy & radiopharmaceuticals.

[46]  Y. Chapuis,et al.  Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group , 2001, World Journal of Surgery.

[47]  S. Lindstedt,et al.  Cytotoxic treatment of adrenocortical carcinoma , 2001, World Journal of Surgery.

[48]  Y. Ma,et al.  Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. , 2001, Leukemia research.

[49]  W. Rainey,et al.  A role for src tyrosine kinase in regulating adrenal aldosterone production. , 2001, Journal of molecular endocrinology.

[50]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[51]  T. Nishida,et al.  Gain‐of‐function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours , 2001, The Journal of pathology.

[52]  F. Beuschlein,et al.  Molecular adrenocortical tumourigenesis , 2000, European journal of clinical investigation.

[53]  A. Kasperlik-Załuska.  Clinical results of the use of mitotane for adrenocortical carcinoma. , 2000, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[54]  F. Beuschlein,et al.  Multiple endocrine neoplasia type 1 gene expression is normal in sporadic adrenocortical tumors. , 2000, European journal of endocrinology.

[55]  P. Lichter,et al.  Adrenocortical carcinoma is characterized by a high frequency of chromosomal gains and high‐level amplifications , 2000, Genes, chromosomes & cancer.

[56]  T. Hongyo,et al.  Specific c-kit mutations in sinonasal natural killer/T-cell lymphoma in China and Japan. , 2000, Cancer research.

[57]  G. Miller,et al.  Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma , 2000, Cancer.

[58]  A. Latronico,et al.  Adrenocortical carcinoma , 2000, Cancer.

[59]  J. Rastad,et al.  PET imaging of adrenal cortical tumors with the 11beta-hydroxylase tracer 11C-metomidate. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[60]  N. Tritos,et al.  Clinical Features and Prognostic Factors Associated with Adrenocortical Carcinoma: Lahey Clinic Medical Center Experience , 2000, The American surgeon.

[61]  M. Brennan,et al.  Long-Term Survival After Complete Resection and Repeat Resection in Patients With Adrenocortical Carcinoma , 1999, Annals of Surgical Oncology.

[62]  M. Bergström,et al.  PET with [11C]-Metomidate for the Visualization of Adrenocortical Tumors and Discrimination from Other Lesions. , 1999, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[63]  E. Speel,et al.  Analysis of genomic alterations in sporadic adrenocortical lesions. Gain of chromosome 17 is an early event in adrenocortical tumorigenesis. , 1999, The American journal of pathology.

[64]  S. Hirota,et al.  Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. , 1999, Cancer research.

[65]  G. Altavilla,et al.  Inactivation of the p16 tumor suppressor gene in adrenocortical tumors. , 1999, The Journal of clinical endocrinology and metabolism.

[66]  B. Alfano,et al.  Imaging of adrenal tumors using FDG PET: comparison of benign and malignant lesions. , 1999, AJR. American journal of roentgenology.

[67]  L. Rönnstrand,et al.  Identification of Tyr-703 and Tyr-936 as the primary association sites for Grb2 and Grb7 in the c-Kit/stem cell factor receptor. , 1999, The Biochemical journal.

[68]  J. Reilly,et al.  c‐kit proto‐oncogene exon 8 in‐frame deletion plus insertion mutations in acute myeloid leukaemia , 1999, British journal of haematology.

[69]  C. Moskaluk,et al.  Activating c-kit gene mutations in human germ cell tumors. , 1999, The American journal of pathology.

[70]  M. Boscaro,et al.  Comment--Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma? , 1999, The Journal of clinical endocrinology and metabolism.

[71]  C. Larsson,et al.  Genotyping of adrenocortical tumors: very frequent deletions of the MEN1 locus in 11q13 and of a 1-centimorgan region in 2p16. , 1999, The Journal of clinical endocrinology and metabolism.

[72]  L. Dogliotti,et al.  Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma , 1998, Cancer.

[73]  A. Porter,et al.  Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis , 1998, Oncogene.

[74]  E. Baudin,et al.  Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. Réseau Comète INSERM. , 1998, British Journal of Cancer.

[75]  S. Lindstedt,et al.  Adrenocortical Carcinoma: Surgery and Mitotane for Treatment and Steroid Profiles for Follow-up , 1998, World Journal of Surgery.

[76]  M. Bergström,et al.  In vitro and in vivo primate evaluation of carbon-11-etomidate and carbon-11-metomidate as potential tracers for PET imaging of the adrenal cortex and its tumors. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[77]  D. Arber,et al.  Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. , 1998, Human pathology.

[78]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[79]  P. Black,et al.  Detection of activated platelet-derived growth factor receptors in human meningioma. , 1997, Cancer research.

[80]  G. Chrousos,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Deletion of the Adrenocorticotropin Receptor Gene in Human Adrenocortical Tumors: Implications for Tumorigenesis* , 2022 .

[81]  X. Bertagna,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Structural and Functional Abnormalities at 11p15 Are Associated with the Malignant Phenotype in Sporadic Adrenocortical Tumors: Study on a Series , 2022 .

[82]  M. Boscaro,et al.  Adrenocortical carcinoma: experience in 45 patients. , 1997, Oncology.

[83]  P. Heikkilä,et al.  Ribonucleic acid expression of the clustered imprinted genes, p57KIP2, insulin-like growth factor II, and H19, in adrenal tumors and cultured adrenal cells. , 1997, The Journal of clinical endocrinology and metabolism.

[84]  R. Coleman,et al.  Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. , 1997, AJR. American journal of roentgenology.

[85]  S. Nilsson,et al.  Biological characteristics of adrenocortical carcinoma: a study of p53, IGF, EGF-r, Ki-67 and PCNA in 17 adrenocortical carcinomas. , 1997, Anticancer research.

[86]  K. Morohashi,et al.  Identical origin of adrenal cortex and gonad revealed by expression profiles of Ad4BP/SF‐1 , 1996, Genes to cells : devoted to molecular & cellular mechanisms.

[87]  J. Zidan,et al.  Treatment of metastatic adrenal cortical carcinoma with etoposide (VP-16) and cisplatin after failure with o,p'DDD. Clinical case reports. , 1996, American journal of clinical oncology.

[88]  P. Hahn,et al.  An imaging algorithm for the differential diagnosis of adrenal adenomas and metastases. , 1995, AJR. American journal of roentgenology.

[89]  Y. Suzuki,et al.  Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[90]  J. Rastad,et al.  Immunohistochemical expression of insulin-like growth factor 1 and its receptor in normal and neoplastic human adrenal cortex. , 1995, Anticancer research.

[91]  R. Kloos,et al.  Incidentally discovered adrenal masses. , 1995, Cancer treatment and research.

[92]  L. Dogliotti,et al.  Cytotoxic chemotherapy for adrenocortical carcinoma. , 1995, Minerva endocrinologica.

[93]  E. Kaplan,et al.  Point mutations of ras genes in human adrenal cortical tumors: Absence in adrenocortical hyperplasia , 1994, World Journal of Surgery.

[94]  G. Fleuren,et al.  Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. , 1994, British Journal of Cancer.

[95]  D. Driscoll,et al.  Adrenal adenocarcinoma: A review of 53 cases , 1994, Journal of surgical oncology.

[96]  G. Chrousos,et al.  p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. , 1994, The Journal of clinical endocrinology and metabolism.

[97]  M. Wooten,et al.  Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature , 1993, Cancer.

[98]  V. Ilvesmäki,et al.  Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: high IGF-II expression in functional adrenocortical carcinomas. , 1993, The Journal of clinical endocrinology and metabolism.

[99]  R. Fleischman.  From white spots to stem cells: the role of the Kit receptor in mammalian development. , 1993, Trends in genetics : TIG.

[100]  P. Kleihues,et al.  p53 Mutations in sporadic adrenocortical tumors , 1993, International journal of cancer.

[101]  K. Hess,et al.  Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer , 1993, Cancer.

[102]  M. Brennan,et al.  An eleven-year experience with adrenocortical carcinoma. , 1992, Surgery.

[103]  L. Dogliotti,et al.  Favorable Response of Metastatic Adrenocortical Carcinoma to Etoposide, Adriamycin and Cisplatin (EAP) Chemotherapy. Report of two Cases , 1992, Tumori.

[104]  J. Rastad,et al.  Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type 1. , 1992, The Journal of clinical endocrinology and metabolism.

[105]  C. Heldin,et al.  Expression of platelet-derived growth factor-beta receptors on human fibroblasts. Regulation by recombinant platelet-derived growth factor-BB, IL-1, and tumor necrosis factor-alpha. , 1992, Journal of immunology.

[106]  T. Hogan,et al.  Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma. , 1991, Surgery.

[107]  A. Gazdar,et al.  Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas. , 1991, The Journal of clinical endocrinology and metabolism.

[108]  M. Schlumberger,et al.  5‐Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma , 1991, Cancer.

[109]  J. Norton,et al.  Recurrent or metastatic disease in select patients with adrenocortical carcinoma. Aggressive resection vs chemotherapy. , 1991, Archives of surgery.

[110]  J. Rastad,et al.  Adrenocortical carcinoma. A retrospective study of a rare tumor with a poor prognosis. , 1990, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[111]  B. Hogan,et al.  Embryonic expression of a haematopoietic growth factor encoded by the SI locus and the ligand for c-kit , 1990, Nature.

[112]  P. Leder,et al.  The hematopoietic growth factor KL is encoded by the SI locus and is the ligand of the c-kit receptor, the gene product of the W locus , 1990, Cell.

[113]  L Hagenäs,et al.  Steroid profile in urine: a useful tool in the diagnosis and follow up of adrenocortical carcinoma. , 1990, Acta endocrinologica.

[114]  E. Rota Kops,et al.  Performance characteristics of an eight-ring whole body PET scanner. , 1990, Journal of computer assisted tomography.

[115]  P Blondeau,et al.  Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. , 1990, The New England journal of medicine.

[116]  Joseph Schlessinger,et al.  Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.

[117]  J. Rastad,et al.  Expression of platelet-derived growth factor beta-receptors on stromal tissue cells in human carcinoid tumors. , 1990, Cancer research.

[118]  A. Bernstein,et al.  Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice--evidence for an impaired c-kit kinase in mutant mice. , 1989, Genes & development.

[119]  C. Heldin,et al.  Binding of different dimeric forms of PDGF to human fibroblasts: evidence for two separate receptor types. , 1988, The EMBO journal.

[120]  Heikki Joensuu,et al.  Florodeoxyglucose imaging: A method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors , 1988 .

[121]  G. Åkerström,et al.  Treatment of hormone‐producing adrenocortical cancer with o,p'DDD and streptozocin , 1987, Cancer.

[122]  John E. Murphy,et al.  A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family , 1986, Nature.

[123]  P M Copeland,et al.  The incidentally discovered adrenal mass. , 1983, Annals of surgery.

[124]  H. vanSlooten,et al.  CAP (cyclophosphamide, doxorubicin, and cisplatin) regimen in adrenal cortical carcinoma. , 1983 .

[125]  Weiss Rb.  Streptozocin: a review of its pharmacology, efficacy, and toxicity. , 1982 .

[126]  S. Legha,et al.  Cytotoxic chemotherapy in adrenal cortical carcinoma. , 1980, Cancer treatment reports.

[127]  M. Boileau,et al.  Adrenal cortical carcinoma. , 1978, The Journal of urology.

[128]  E. Wilander,et al.  Distribution of labelled streptozotocin in mice: uptake and retention in pancreatic islets. , 1976, The Journal of endocrinology.

[129]  D. A. Macfarlane.  Cancer of the adrenal cortex; the natural history, prognosis and treatment in a study of fifty-five cases. , 1958, Annals of the Royal College of Surgeons of England.

[130]  M. Dietel,et al.  Immunocytochemical differential diagnosis of adrenocortical neoplasms using the monoclonal antibody D11 , 2005, Virchows Archiv A.

[131]  T. Seito,et al.  Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human: immunohistochemical study on formalin-fixed, paraffin-embedded tissues , 2004, Virchows Archiv.

[132]  Linda Ng,et al.  Adrenocortical carcinoma: diagnosis, evaluation and treatment. , 2003, The Journal of urology.

[133]  M. Cole,et al.  OPEC/OJEC for stage 4 neuroblastoma in children over 1 year of age. , 2001, Medical and pediatric oncology.

[134]  B. Allolio,et al.  MEN 1 Gene Analysis in Sporadic Adrenocortical Neoplasms * , 1998 .

[135]  R. Kloos,et al.  Diagnostic Dilemma of Small Incidentally Discovered Adrenal Masses: Role for 131I-6β-Iodomethyl-norcholesterol Scintigraphy , 1997, World Journal of Surgery.

[136]  M. Goldberg,et al.  Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. , 1995, Radiology.

[137]  R. Bukowski,et al.  Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[138]  M. Aricò,et al.  Partial response after intensive chemotherapy for adrenal cortical carcinoma in a child. , 1992, Medical and pediatric oncology.

[139]  P. Crock,et al.  Combination chemotherapy for adrenal carcinoma: response in a 5 1/2-year-old male. , 1989, Medical and pediatric oncology.

[140]  H. V. van Slooten,et al.  The treatment of adrenocortical carcinoma with o,p'-DDD: prognostic implications of serum level monitoring. , 1984, European journal of cancer & clinical oncology.

[141]  R. Connelly,et al.  Third national cancer survey: incidence data. , 1975, National Cancer Institute monograph.